Bioness Announces First Procedure of StimRouter Neuromodulation

Bioness has announced its first commercial procedure of its StimRouter Neuromodulation System since receiving FDA clearance.

The system treats chronic, intractable pain of peripheral nerve origin as an addition to other modes of therapy.  Bioness says the system is the only implantable neuromodulation device indicated to treat chronic pain of peripheral nerve origin.

The implant is controlled by a hand-held wireless patient programmer.

Bioness says chronic pain affects an estimated 50 million people and contributes $150 billion in annual costs to the U.S. healthcare system. — Michael Cipriano